Clinical Trial: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Cancer
Study Type: INTERVENTIONAL
Official Title: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy for Metastatic Urothelial Carcinoma With Stable or Responding Disease Following Platinum-based Chemothera
Brief Summary:
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based chemotherapy
Read more